Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Enteral Treatment
1.2.3 Parenteral Treatment
1.2.4 Topical Treatment
1.3 Market by Application
1.3.1 Global Gram-Negative Bacterial Infection Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Perspective (2018-2033)
2.2 Gram-Negative Bacterial Infection Therapeutics Growth Trends by Region
2.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Gram-Negative Bacterial Infection Therapeutics Market Dynamics
2.3.1 Gram-Negative Bacterial Infection Therapeutics Industry Trends
2.3.2 Gram-Negative Bacterial Infection Therapeutics Market Drivers
2.3.3 Gram-Negative Bacterial Infection Therapeutics Market Challenges
2.3.4 Gram-Negative Bacterial Infection Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue
3.1.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Gram-Negative Bacterial Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gram-Negative Bacterial Infection Therapeutics Revenue
3.4 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio
3.4.1 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gram-Negative Bacterial Infection Therapeutics Revenue in 2022
3.5 Gram-Negative Bacterial Infection Therapeutics Key Players Head office and Area Served
3.6 Key Players Gram-Negative Bacterial Infection Therapeutics Product Solution and Service
3.7 Date of Enter into Gram-Negative Bacterial Infection Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Type
4.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2024-2033)
5 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Application
5.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Gram-Negative Bacterial Infection Therapeutics Market Size (2018-2033)
6.2 North America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023)
6.4 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gram-Negative Bacterial Infection Therapeutics Market Size (2018-2033)
7.2 Europe Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023)
7.4 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size (2018-2033)
9.2 Latin America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Detail
11.1.2 Baxter Business Overview
11.1.3 Baxter Gram-Negative Bacterial Infection Therapeutics Introduction
11.1.4 Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.1.5 Baxter Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Gram-Negative Bacterial Infection Therapeutics Introduction
11.2.4 Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Introduction
11.3.4 GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.3.5 GlaxoSmithKline Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Gram-Negative Bacterial Infection Therapeutics Introduction
11.4.4 Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Gram-Negative Bacterial Infection Therapeutics Introduction
11.5.4 Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Gram-Negative Bacterial Infection Therapeutics Introduction
11.6.4 Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.6.5 Takeda Recent Development
11.7 Nektar Therapeutics
11.7.1 Nektar Therapeutics Company Detail
11.7.2 Nektar Therapeutics Business Overview
11.7.3 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Introduction
11.7.4 Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.7.5 Nektar Therapeutics Recent Development
11.8 Sumitomo
11.8.1 Sumitomo Company Detail
11.8.2 Sumitomo Business Overview
11.8.3 Sumitomo Gram-Negative Bacterial Infection Therapeutics Introduction
11.8.4 Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.8.5 Sumitomo Recent Development
11.9 Targeted Genetics
11.9.1 Targeted Genetics Company Detail
11.9.2 Targeted Genetics Business Overview
11.9.3 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Introduction
11.9.4 Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
11.9.5 Targeted Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Enteral Treatment
Table 3. Key Players of Parenteral Treatment
Table 4. Key Players of Topical Treatment
Table 5. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2018-2023)
Table 9. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2024-2033)
Table 11. Gram-Negative Bacterial Infection Therapeutics Market Trends
Table 12. Gram-Negative Bacterial Infection Therapeutics Market Drivers
Table 13. Gram-Negative Bacterial Infection Therapeutics Market Challenges
Table 14. Gram-Negative Bacterial Infection Therapeutics Market Restraints
Table 15. Global Gram-Negative Bacterial Infection Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players (2018-2023)
Table 17. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2022)
Table 18. Ranking of Global Top Gram-Negative Bacterial Infection Therapeutics Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Gram-Negative Bacterial Infection Therapeutics Product Solution and Service
Table 22. Date of Enter into Gram-Negative Bacterial Infection Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2018-2023)
Table 26. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2024-2033)
Table 28. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2018-2023)
Table 30. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2024-2033)
Table 32. North America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 47. Baxter Company Detail
Table 48. Baxter Business Overview
Table 49. Baxter Gram-Negative Bacterial Infection Therapeutics Product
Table 50. Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 51. Baxter Recent Development
Table 52. Sanofi Company Detail
Table 53. Sanofi Business Overview
Table 54. Sanofi Gram-Negative Bacterial Infection Therapeutics Product
Table 55. Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 56. Sanofi Recent Development
Table 57. GlaxoSmithKline Company Detail
Table 58. GlaxoSmithKline Business Overview
Table 59. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Product
Table 60. GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 61. GlaxoSmithKline Recent Development
Table 62. Novartis Company Detail
Table 63. Novartis Business Overview
Table 64. Novartis Gram-Negative Bacterial Infection Therapeutics Product
Table 65. Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Gram-Negative Bacterial Infection Therapeutics Product
Table 70. Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Takeda Company Detail
Table 73. Takeda Business Overview
Table 74. Takeda Gram-Negative Bacterial Infection Therapeutics Product
Table 75. Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 76. Takeda Recent Development
Table 77. Nektar Therapeutics Company Detail
Table 78. Nektar Therapeutics Business Overview
Table 79. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Product
Table 80. Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 81. Nektar Therapeutics Recent Development
Table 82. Sumitomo Company Detail
Table 83. Sumitomo Business Overview
Table 84. Sumitomo Gram-Negative Bacterial Infection Therapeutics Product
Table 85. Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 86. Sumitomo Recent Development
Table 87. Targeted Genetics Company Detail
Table 88. Targeted Genetics Business Overview
Table 89. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Product
Table 90. Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023) & (US$ Million)
Table 91. Targeted Genetics Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gram-Negative Bacterial Infection Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Enteral Treatment Features
Figure 4. Parenteral Treatment Features
Figure 5. Topical Treatment Features
Figure 6. Global Gram-Negative Bacterial Infection Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Application: 2022 VS 2033
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Gram-Negative Bacterial Infection Therapeutics Report Years Considered
Figure 12. Global Gram-Negative Bacterial Infection Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Gram-Negative Bacterial Infection Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region: 2022 VS 2033
Figure 15. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players in 2022
Figure 16. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue in 2022
Figure 18. North America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2018-2033)
Figure 20. United States Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2018-2033)
Figure 24. Germany Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2018-2033)
Figure 32. China Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2018-2033)
Figure 40. Mexico Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2018-2033)
Figure 44. Turkey Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Baxter Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 47. Sanofi Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 48. GlaxoSmithKline Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 49. Novartis Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 50. Pfizer Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 51. Takeda Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 52. Nektar Therapeutics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 53. Sumitomo Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 54. Targeted Genetics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed